|This article needs additional citations for verification. (June 2014)|
|Traded as||NYSE MKT: NBY|
|Headquarters||Emeryville, California, United States|
|Ron Najafi, Ph.D., CEO
Tom Paulson, M.B.A., CFO
Keith R. Bley, Ph.D., Sr. VP of Product Development
Russell Hoon, Sr. VP of Advanced Wound Care
David Stroman, Ph.D., Sr. VP, Ophthalmology
Roy Wu, M.B.A., Sr. VP, Business Development
Glenn Moro,VP, Sales and Marketing Avenova
Number of employees
NovaBay Pharmaceuticals, Inc. is an Emeryville, California based clinical-stage biopharmaceutical company, focused on developing novel, fast-acting, synthetic anti-infectives compounds. These compounds are designed to mimic the body's defense system against infection and will treat and prevent a wide range of local, non-systemic infections with a low likelihood of developing bacterial resistance.
The Company announced a refinement of business focus on products for the eye care market. This refinement is designed to deliver commercial and business success for the company in near term. NovaBay has Accelerated commercialization of its breakthrough Avenova™ product (formerly known as i-Lid Cleanser) and plans to introduce new and innovative eye care products already in development in the next 12-18 months.
Avenova™ was cleared by FDA for lid and lash cleansing as part of a regimen for Blepharitis. "NovaBay Avenova has a low toxicity but kills eyelid bacteria in dry eye or blepharitis patients.".
Another product of NovaBay, NeutroPhase® is effective in treatment of 'Necrotizing Fasciitis' "Treatment of Acute Necrotizing Fasciitis Using Negative Pressure Wound Therapy and Adjunctive NeutroPhase Irrigation Under the Foam".. The National Necrotizing Fasciitis Foundation (NNFF)*www
NovaBay Pharmaceuticals, Inc. was founded by Ron Najafi, an organic chemist who had previously worked for several pharmaceutical, chemical and biotech companies in the U.S. In 1996 he with the help of his wife Kelly Farhangi Najafi founded CP Lab Safety to market a product to trap emissions from open waste containers in laboratories. When running CP Lab Safety, Najafi became intrigued by hypochlorous acid, an antimicrobial substance produced by White Blood Cells during oxidative burst. HOCl and other chlorine-containing chemicals fight invading microbes. These natural substances rapidly oxidize the cell walls of bacteria and the protein coats of viruses, rendering them inactive. Najafi started NovaBay Pharmaceuticals in 2000 to create a stable version of HOCl."Hypochlorous Acid as a Potential Wound Care Agent Part I" (PDF). Najafi, chemistry Nobel Laureate Herbert C. Brown, and Purdue University's Professor Dale Margerum recruited Dr. Lu Wang to NovaBay, where she is now Director of Product Development. She was able to develop the stable version of pure hypochlorous acid, without bleach impurities, which became NovaBay’s first product NeutroPhase®"Hypochlorous Acid as a Potential Wound Care Agent Part II" (PDF). "NeutroPhase® in chronic non-healing wounds" (PDF). "Treatment of Acute Necrotizing Fasciitis Using Negative Pressure Wound Therapy and Adjunctive NeutroPhase Irrigation Under the Foam".[not in citation given] and cleared by the Food and Drug Administration in 2010. The product successfully treats a variety of chronic non-healing wounds without the use of standard antibiotics. NovaBay announced two new products named CelleRx™ for Plastic Surgery and i-Lid™ Cleanser (Now Avenova) that was cleared by FDA for lid and lash cleansing as part of a regimen for Blepharitis. "NovaBay Avenova has a low toxicity but kills eyelid bacteria in dry eye or blepharitis patients.".
As of September 30, 2013[update], the members of the board of directors of NovaBay Pharmaceuticals were: Ron Najafi, Ph.D., Chairman and CEO, Charles J. Cashion, Paul E. Freiman, Gail Maderis, T. Alex McPherson, M.D., Ph.D., Massimo Radaelli, Ph.D., Mark Sieczkarek and Tony Wicks.
Products on the market
Products under development
NovaBay developed a method for making a stable pure form of hypochlorous acid (HOCl), a substance produced by the immune system as an effective first defense against microbial invaders. The company calls their proprietary formulation Neutrox. The company's top chemists also created a related family of compounds called Aganocides®. Lab tests show that Neutrox and the Aganocide compounds have potent anti-bacterial and anti-viral action, yet are completely safe and don’t lead to the evolution of resistant bacteria. Researchers have shown that HOCl is effective at killing the bacteria that cause anthrax and dangerous hospital-acquired infections. The lead Aganocide is Auriclosene (NVC-422). Aganocides mimic potent bacterial-killing chemicals that the human immune system produces when it first encounters an invader.
Those properties mean that the technology has tremendous medical utility. The company has shown that they can help save the lives and limbs of victims of flesh-eating disease, reduce the problems of encrustation and blockage in in-dwelling urinary catheters, and bring relief to patients suffering from common eye conditions. Novabay intends to keep pursuing all these applications because of the positive impact on patients’ lives. Ophthalmology is by far the greatest opportunity for NovaBay to help an estimated 40 million Americans that suffer from such common conditions as blepharitis, meibomian gland dysfunction, or dry eye syndrome. NovaBay's prescription eyelid hygiene product, Avenova™, offers major advantages over existing treatments, including antibiotics, steroids and detergent-based lid wipes. Doctors and patients report that Avenova has finally brought relief after years of suffering.
The lead Aganocide compound Auriclosene (NVC-422) is also being developed for the global veterinary markets to improve animal health.
- "NYSE EURONEXT: NovaBay Pharmaceuticals, Inc.".
- "510(k) Summary NeutroPhase® Skin and Wound Cleaner OTC" (PDF).
- NovaBay’s new Advanced i-Lid™ Cleanser has been Cleared by the FDA*for Cleaning, Removing Debris and Microbes from the Skin around the Eyes, the Eyelids and Eyelashes eyelid and lash cleansing as part of a regimen for Blepharitis."
- Steven E. F. Brown (February 26, 2014). "NovaBay Pharmaceuticals makes deal for flesh-eating bacteria cleanser". San Francisco Business Times. Retrieved June 19, 2014.
- for Plastic Surgery"
- Hayden, Faith (May 2012). "Perioperative pharmacology Entering into the post-antibiotic era". ASCRS EyeWorld. American Society of Cataract and Refractive Surgery. Retrieved 3 October 2013.
- "NovaBay Pharmaceuticals and Virbac Enter Into a Collaboration and License Agreement for Animal Health".
.doctors .avenova .com
- NovaBay Pharmaceuticals, Inc., "The New York Times"